Drug Approval | December 12, 2022
Alembic receives USFDA final Approval for Desonide Cream
Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA
Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)
Subscribe To Our Newsletter & Stay Updated
